+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Primary Biliary Cholangitis Therapeutics Market 2019-2023 - Product Image

Global Primary Biliary Cholangitis Therapeutics Market 2019-2023

  • ID: 4792933
  • Report
  • June 2019
  • Region: Global
  • 131 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan Plc
  • Eli Lilly and Co.
  • MORE
Global Primary Biliary Cholangitis Therapeutics Market: About this market

Primary biliary cholangitis is a chronic autoimmune disease in which intrahepatic bile ducts are damaged over a period of time. This primary biliary cholangitis therapeutics market analysis considers sales of OCALIVA, ursodiol, and others. Our analysis also considers the sales of primary biliary cholangitis therapeutics in Asia, Europe, North America, ROW. In 2018, the OCALIVA segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as strong efficacy of OCALIVA to target the T-cells that are known to cause primary biliary cholangitis will play a significant role in the OCALIVA segment to maintain its market position. Also, our global primary biliary cholangitis therapeutics market report looks at factors such as increasing collaborations, growing risk factors, and rising awareness campaigns to reduce further complications. However, asymptomatic nature of the disease, lack of approved therapies, and availability of alternative therapies may hamper the growth of the primary biliary cholangitis therapeutics industry over the forecast period.

Global Primary Biliary Cholangitis Therapeutics market: Overview

Growing awareness campaigns to reduce further complications

To increase the awareness of the indication, various organizations and the vendors in the global primary biliary cholangitis therapeutics market are conducting awareness campaigns. For instance, the PBCers Organization is a non-profit organization that focuses on increasing the awareness of the indication globally. The organization also focuses on funding the research on the development of novel therapies to treat primary biliary cholangitis. This will boost the sales of primary biliary cholangitis therapeutics and lead to the expansion of the global primary biliary cholangitis therapeutics market at a CAGR of close to 10% during the forecast period.

Advent of regenerative therapy

Research on regenerative therapy is gaining traction as the liver transplant method of treatment causes post-surgery complications to patients. Also, at present, there is no cure for the indication other than liver transplant due to the recurring nature of the disease. This is encouraging researchers to conduct study on stem cell transplantation, which can replace destroyed cells in the bile duct. This ongoing research is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of few major players, the global primary biliary cholangitis therapeutics market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics manufacturers, that include Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan Plc
  • Eli Lilly and Co.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • OCALIVA - Market size and forecast 2018-2023
  • Ursodiol - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Strong pipeline
  • Increasing drug designations
  • Advent of regenerative therapy
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott Laboratories
  • Allergan Plc
  • Eli Lilly and Co.
  • Intercept Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 16: EXPLORE

List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global primary biliary cholangitis therapeutics market pipeline: Overview
Exhibit 18: Global primary biliary cholangitis therapeutics market pipeline: Snapshot
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: OCALIVA - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: OCALIVA - Year-over-year growth 2019-2023 (%)
Exhibit 23: Ursodiol - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Ursodiol - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Abbott Laboratories - Vendor overview
Exhibit 52: Abbott Laboratories - Business segments
Exhibit 53: Abbott Laboratories - Organizational developments
Exhibit 54: Abbott Laboratories - Geographic focus
Exhibit 55: Abbott Laboratories - Segment focus
Exhibit 56: Abbott Laboratories - Key offerings
Exhibit 57: Abbott Laboratories - Key customers
Exhibit 58: Allergan Plc - Vendor overview
Exhibit 59: Allergan Plc - Business segments
Exhibit 60: Allergan Plc - Organizational developments
Exhibit 61: Allergan Plc - Geographic focus
Exhibit 62: Allergan Plc - Segment focus
Exhibit 63: Allergan Plc - Key offerings
Exhibit 64: Allergan Plc - Key customers
Exhibit 65: Eli Lilly and Co. - Vendor overview
Exhibit 66: Eli Lilly and Co. - Business segments
Exhibit 67: Eli Lilly and Co. - Organizational developments
Exhibit 68: Eli Lilly and Co. - Geographic focus
Exhibit 69: Eli Lilly and Co. - Segment focus
Exhibit 70: Eli Lilly and Co. - Key offerings
Exhibit 71: Eli Lilly and Co. - Key customers
Exhibit 72: Intercept Pharmaceuticals Inc. - Vendor overview
Exhibit 73: Intercept Pharmaceuticals Inc. - Business segments
Exhibit 74: Intercept Pharmaceuticals Inc. - Organizational developments
Exhibit 75: Intercept Pharmaceuticals Inc. - Geographic focus
Exhibit 76: Intercept Pharmaceuticals Inc. - Key offerings
Exhibit 77: Intercept Pharmaceuticals Inc. - Key customers
Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan Plc
  • Eli Lilly and Co.
  • MORE
The following companies are recognised as the key players in the global primary biliary cholangitis therapeutics market: Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of regenerative therapy”.

According to the report, one of the major drivers for this market is the growing awareness campaigns to reduce further complications.

Further, the report states that one of the major factors hindering the growth of this market is the lack of approved therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Abbott Laboratories
  • Allergan Plc
  • Eli Lilly and Co.
  • Intercept Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll